Actimed Receives Investment from Mankind Pharma

Mankind Pharma announced earlier this week that an investment has been made into Actimed Therapeutics, a UK pharmaceutical business focused on the clinical-stage niche.

The company is concentrated on introducing innovation to the way cancer cachexia is currently dealt with in medical environments, which is a current gap in the market, and a proficient medical requirement for individuals suffering with cancer and other illnesses that cause muscle wasting.

Mankind Pharma has not yet revealed the exact quantity of financial investment.

Actimed stated in a declaration that the funding will be used to assist the company’s strategic clinical development initiatives. President of Sales & Marketing at Mankind Pharma, Atish Majumdar, has taken up a new position on the board of directors of Actimed Therapeutics as a result of the transaction.

Mr Majumdar expressed that they have been “inspired by Actimed’s novel pipeline and recognise the significant potential of S-pindolol benzoate as a new therapeutic option for cancer cachexia. We look forward to working with the experienced board and leadership team of Actimed to bring innovative new therapies to patients with cachexia.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.